TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04879810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy and biopsy, blood work
Description: Flexible tube up lower colon, blood draws, quality of life questionnaires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy and biopsy, blood work
Description: Flexible tube up lower colon, blood draws, quality of life questionnaires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy and biopsy, blood work
Description: Flexible tube up lower colon, blood draws, quality of life questionnaires
Study: NCT04726202

Intervention type: OTHER
Intervention: Standard procedure
Description: Coding of cases follows the standard procedures established at the hospital

Intervention type: OTHER
Intervention: precoding
Description: Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report.
Study: NCT01580878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine Hydrochloride Cream, 1%
Description: Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
Study: NCT02428062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 5-10 mcg intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
Study: NCT03756129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: Different dosages and different regimen for MIJ821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: Different dosages and different regimen for MIJ821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: Different dosages and different regimen for MIJ821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: Different dosages and different regimen for MIJ821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Infusion
Study: NCT02369640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Error-management training vs error-avoidance training. Defined by training instructions.
Description: . Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Error-management training vs error-avoidance training. Defined by training instructions.
Description: . Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!
Study: NCT01905137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-Botulinum Toxin Type A
Description: Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00269893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 0.25 mg/kg of body weight of abciximab either bolus or infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 0.25 mg/kg of body weight of abciximab either bolus or infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo soulution either bolus or infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo soulution either bolus or infusion.
Study: NCT03914729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Closure
Description: A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gluteus Maximus Fascia Plasty Flap
Description: A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
Study: NCT01365832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
Study: NCT02105584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of LAA closure device
Study: NCT03857074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Light Exposure
Description: To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
Study: NCT00758277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam (Keppra)
Description: levetiracetam daily application 1500-2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study: NCT02215382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine+atropine
Description: neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
Study: NCT01771640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: Intrathecal injection of mesenchymal stem cells in patients with ALS
Study: NCT04193124

Intervention type: DIAGNOSTIC_TEST
Intervention: transcranial doppler.
Description: Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
Study: NCT02864394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
Study: NCT00921596

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac operation with totally endoscopic method
Description: Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
Study: NCT05742022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phospholipovit
Description: 500 mg orally 2 times a day, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mg orally 2 times a day, for 12 weeks
Study: NCT00081497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase beta
Description: 1.0 mg/kg every 2 weeks
Study: NCT03409796

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gluten
Description: Gluten powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gluten
Description: Gluten powder.
Study: NCT00727467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Cueing Device
Description: Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Cueing Device
Description: Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
Study: NCT02044354

Intervention type: DRUG
Group type: OTHER
Intervention: Taxotere

Intervention type: DRUG
Group type: OTHER
Intervention: Taxotere

Intervention type: DRUG
Group type: OTHER
Intervention: Jevtana

Intervention type: DRUG
Group type: OTHER
Intervention: Jevtana
Study: NCT01638455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive device
Description: Noninvasive device
Study: NCT03306914

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Albumin resuscitation
Description: Albumin 5% is used as the intra-operative colloid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch resuscitation
Description: Hydroxyethyl starch 6% is used as the intra-operative colloid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 5%
Description: Infusion of Albumin 5% intra-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6%
Description: Infusion of Hydroxyethylstarch 6% intra-operatively
Study: NCT01212835

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: no ring
Description: Open roux-en-Y gastric bypass not banded

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGBP-RING
Description: Vertical Roux-en-Y banded gastric bypass
Study: NCT03084211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light exercise discharge instructions
Description: Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
Study: NCT01112826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 650 mg/m2 twice every day for 1 year.
Study: NCT03422913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled low central venous pressure
Description: Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still \>5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) \> 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
Study: NCT00907595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Study: NCT01769742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early mobility bundle
Study: NCT03641417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01
Description: Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as GLWL-01, but no active ingredient
Study: NCT05974241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate, aripiprazole, and combination
Description: Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
Study: NCT01544296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01873937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Red LED
Description: Phototherapy with red LED on temporomandibular area

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INFRARED LED
Description: Phototherapy with infrared LED on temporomandibular area

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: Phototherapy with LASER INFRARED on temporomandibular area
Study: NCT02288286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study: NCT04391374

Intervention type: PROCEDURE
Intervention: an arterial reconstructive procedure

Intervention type: PROCEDURE
Intervention: an arterial reconstructive procedure
Study: NCT00836368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gamma-tocopherol
Description: oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
Study: NCT00966654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (7-36) amide
Description: 1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
Study: NCT03684616

Intervention type: DRUG
Intervention: Statin
Description: continuous statin treatment for 3 months prior to cardiac arrest

Intervention type: DRUG
Intervention: Statin
Description: continuous statin treatment for 3 months prior to cardiac arrest
Study: NCT03400735

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir/clavulanic acide 300/125 mg film-coated tablets
Description: Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300Mg Capsule
Description: Cefdinir is used as comparator
Study: NCT03612817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost/timolol fixed combination
Description: Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost/timolol fixed combination
Description: Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
Study: NCT03737695

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo clinical information collection
Study: NCT04441905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
Study: NCT03742076

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-dose prebiotic
Description: This is a spray-dried powder, yellowish-white in color, that is dissolvable.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose prebiotic
Description: This is a spray-dried powder, yellowish-white in color, that is dissolvable.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder fiber supplement, yellowish-white in color, that is dissolvable.
Study: NCT00972413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
Study: NCT00582439

Intervention type: DEVICE
Group type: OTHER
Intervention: Reamer-Irrigator-Aspirator (RIA)
Description: Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.